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Abstract
Purpose Retinoblastoma (RB) is the most common primary intraocular tumor in children. Chemotherapy is currently the 
main method of RB treatment. Unfortunately, RB often becomes chemoresistant and turns lethal. Here, we used in vitro cell 
immunotherapy to explore whether adoptive immunotherapy could be used as a potential treatment for RB. We focused on 
spleen tyrosine kinase (SYK), which is significantly upregulated in RB cells and serves as a marker for RB cells.
Methods Using lentiviruses, we genetically modified dendritic cells (DCs) to express and present the SYK peptide antigen to 
cytotoxic T lymphocytes (CTLs) in vitro. We used SYK-negative cell lines (MDA-MB-231, MCF-10A, and hTERT-RPE1) 
and SYK-positive cell lines (MCF-7 and RB-Y79) to evaluate the specificity and cytotoxicity of DC presented CTLs using 
FACS, live-cell imaging, and RNA interference.
Results The cytotoxicity of CTLs induced by SYK-overexpressing DCs (SYK-DC–CTLs) was enhanced more than three 
times in SYK-positive cell lines compared with SYK-negative cell lines. DCs primed with SYK could drive CTL cytotoxicity 
against SYK-positive cell lines but not against SYK-negative cell lines. Moreover, SYK-silenced RB-Y79 cells successfully 
evaded the cytotoxic attack from SYK-DC–CTLs. However, SYK-DC–CTLs could target SYK overexpressed hTERT-RPE1 
cells, suggesting that SYK is a specific antigen for RB. Furthermore, SYK-DC–CTL exhibited specific cytotoxicity against 
carboplatin-resistant RB-Y79 cells in vitro.
Conclusions Our data showed that SYK could be a potential immunotherapy target mediated by DCs. We propose SYK as 
a candidate target for treatment of chemoresistant RB.
Keywords Retinoblastoma · Spleen tyrosine kinase · Dendritic cells · Cytotoxic T lymphocytes · Autologous adoptive 
immunotherapy
Introduction
Retinoblastoma (RB) is the most common primary intraocu-
lar tumor in children and is initiated by the bi-allelic loss 
of RB gene function (Sachdeva and O’Brien 2012). RB is Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00432-018-2584-x) contains 
supplementary material, which is available to authorized users.
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highly aggressive and leads to intraorbital, intracranial, and 
even systemic metastasis (Shields et al. 2013). Despite the 
advances made in radiation and chemotherapy along with 
surgical resection for the treatment of RB, the prognosis for 
patients with advanced RB remains poor.
Chemotherapy is currently used as first-line treatment 
for RB. Although this strategy could save patient lives, the 
treatment still has several limitations. First, eyeball enuclea-
tion and radiotherapy lead to blindness, disablement, and an 
inferior quality of life. Second, chemotherapy causes serious 
side effects such as myelosuppression, neutropenia, infec-
tion, anemia, and hearing loss. Finally, long-term chemo-
therapy leads to multidrug resistance, which increases the 
chances of recurrence and metastases (Shields et al. 2003). 
These disadvantages indicate the need for new and effective 
therapeutic approaches for RB without limiting side effects.
The spleen tyrosine kinase (SYK) was recently identified 
as one of the most significantly upregulated kinase genes in 
RB (Zhang et al. 2012). SYK is involved in B-cell receptor 
complex signaling in various inflammatory cells and has 
been implicated in hematopoietic cell malignancies (Chen 
et al. 2008; Feldman et al. 2008; Hahn et al. 2009; Young 
et al. 2009). There are two SYK isoforms in tumor cells: the 
full-length SYK (SYK-L) and the alternatively spliced SYK 
transcript (SYK-S). SYK-L can enter the nucleus and sup-
press cancer cell invasiveness, whereas SYK-S is restricted 
to the cytoplasm and could promote tumor progression 
(Wang et al. 2003). SYK is also a proto-oncogene involved 
in RB cell survival. However, SYK is not expressed in either 
retinal progenitor cells or neurons and has no known func-
tion in the developing visual system. These observations 
suggest that this gene might drive RB tumorigenesis (Zhang 
et al. 2012). Thus, SYK could be a suitable candidate for RB 
therapy.
Adoptive immunotherapy has been shown to possess 
great potential as an adjuvant treatment to control cancer 
(Sachdeva and O’Brien 2012). One of the key players in 
mediating the immune response are the dendritic cells 
(DCs), as they prime näive helper and cytotoxic T lympho-
cytes (CTLs) (Ahmed and Bae 2014). DCs can capture, pro-
cess, and present antigens to T cells and trigger a specific 
anti-tumor autoimmune response (Banchereau and Stein-
man 1998). However, malignancies can inactivate DCs by 
expressing immune inhibitory molecules and/or by secreting 
immunosuppressive cytokines, thus leading to ineffective 
antigen presentation to DCs. Ultimately, this inactivation of 
DCs allows tumor cells to evade anti-tumor immunological 
responses (Ahmed and Bae 2014; Nestle 2000). To over-
come this limitation, in vitro-generated functional DCs have 
been intensively researched over the past decade (Palucka 
and Banchereau 2012). These DCs can be loaded with anti-
gens, a procedure that increases DC specificity and enhances 
the targeting and killing of cancer cells (Liu et al. 2013; 
Wang et al. 2013).
In this study, we genetically modified DCs, so they can 
persistently present antigenic epitopes on their surface, thus 
more strongly and specifically stimulating an anti-tumor 
immune response (Alexandrescu et al. 2010). We used len-
tiviral vectors that have been modified to be safely used in 
gene therapy in vivo (Wang et al. 2010). Using this strategy, 
we expressed SYK to prime T lymphocytes. Importantly, the 
DCs transfected with lentiviral vectors can activate specific 
anti-tumor immune responses (Ahmed Ali et al. 2014; Cui 
et al. 2012; Lopes et al. 2006; Wang et al. 2010; Xiao et al. 
2012). We aimed to investigate whether: (1) SYK can be 
used as a specific target for RB; (2) cell immunotherapy 
is an effective and safe approach for RB treatment; and (3) 
presenting DCs with lentivirus could promote T-lympho-
cyte maturation and increase specific cytotoxicity against 
RB-Y79 cells in vitro.
Materials and methods
Cell lines
Human retinoblastoma cells (RB-Y79, ATCC, USA) and 
human retinal pigment epithelium cells (hTERT-RPE1, 
JENNIO Biological Technology, China) were maintained in 
RPMI 1640 (Thermo Fisher Scientific, USA) supplemented 
with 10% fetal bovine serum (FBS, Thermo Fisher Scien-
tific, Australia). Carboplatin-resistant RB-Y79 cells (RB-
Y79-R) were cultured in RPMI 1640 containing 10% FBS 
and 40 µg/ml carboplatin. MDA-MB-231, MCF-10A, and 
MCF-7 breast cancer cell lines were purchased from Shang-
hai Zhong Qiao Xin Zhou Biotechnology Company. Human 
embryonic kidney 293FT cells (Thermo Fisher Scientific, 
USA) were cultured in high glucose DMEM (Thermo Fisher 
Scientific, USA) containing 10% FBS, 0.1 mM MEM Non-
essential Amino Acids (Thermo Fisher Scientific, USA), 
2 mM l-glutamine (Thermo Fisher Scientific, USA), 1 mM 
sodium pyruvate (Thermo Fisher Scientific, USA), and 500 
µg/ml geneticin (G418, Thermo Fisher Scientific, USA).
Production of lentivirus
SYK cDNA (NM003177) was obtained from OriGene Tech-
nologies. The ViraPower™ HiPerform™ Lentiviral TOPO 
Expression Kit (Thermo Fisher Scientific, USA) and 293FT 
cells were used to produce SYK lentivirus, GFP lentivi-
rus, and SYK–GFP lentivirus according to the manufac-
turer’s instructions. The SYK lentivirus, GFP lentivirus, or 
SYK–GFP lentivirus were harvested and filtered through a 
0.45 µm membrane, aliquoted, and stored at − 80 °C until 
use.
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Generation of different types of DC–CTLs
DCs were induced by a previously described method (Wang 
et al. 2013). Briefly, PBMCs were isolated from blood with 
Ficoll–Hypaque (Morecell Biomedical Co. Ltd, Shenzhen, 
China). The adherent PBMCs were cultured in serum-free 
medium for immune cells (MCM-001, Morecell Biomedi-
cal Co. Ltd, Shenzhen, China) supplemented with 100 ng/
ml GM-CSF, 30 ng/ml IL-4, and 5% autologous plasma for 
induction of DCs. The medium was changed every 3 days. 
TNF-α (10 ng/ml) was added to DCs on the 6th day. The 
non-adherent PBMCs were cultured in serum-free medium 
for immune cells containing 1000 U/ml IL-2, 1000 IU/ml 
IFN-γ, 200 ng/ml CD3 monoclonal antibody, and 5% autolo-
gous plasma for generating CTLs.
On the 3rd day of DCs culture, the immature DCs were 
infected by SYK lentivirus or GFP lentivirus at MOI 30 
using 10 µg/ml hexadimethrine bromide (polybrene, Sigma-
Aldrich, St. Louis, USA) (Seitz et al. 1998). 24 h later, the 
medium was replaced by fresh medium. On the 8th day, 
the mature SYK-DCs (DCs infected with SYK lentivirus) 
or GFP-DCs (DCs infected with GFP lentivirus) were 
harvested.
To generate RB-Y79 complete antigen-pulsed DCs 
(Ag-DCs), RB-Y79 lysates were generated by three rapid 
freeze–thaw cycles. Briefly, RB-Y79 cells were resuspended 
in PBS at the density of 1 × 107 cells/ml. The RB-Y79 cells 
in suspension were frozen in liquid nitrogen and disrupted 
by three freeze–thaw cycles. The cell lysis was centrifugated 
for 10 min at 600g. The supernatant (RB-Y79 complete anti-
gen) was collected and stored at − 80 °C. Then, the RB-Y79 
complete antigen was added to immature DCs on the 3rd 
day. 24 h later, the medium was replaced by fresh medium. 
On the 8th day, the mature Ag-DCs were then harvested.
The mature wild-type DCs (WT-DCs), SYK-DCs, 
GFP-DCs, and Ag-DCs were co-cultured with CTLs at 
a ratio of 1:10 (DC: T) for another 6–8 days to generate 
WT-DC–CTLs, SYK-DC–CTLs, GFP-DC–CTLs, and 
Ag-DC–CTLs separately.
Flow cytometry
DCs were identified with a panel of antibodies: CD80-PE, 
CD83-APC, and CD86-FITC (BD Bioscience). T lympho-
cytes were phenotyped with antibodies against CD3, CD8, 
CD38, HLA–DR, and T-cell receptor (TCR)-αβ (BD Bio-
sciences, New York, USA). A mouse IgG (PE/FITC/APC) 
was used as a negative control in all assays. Flow cytometric 
analysis was performed on a FACSCalibur Flow Cytometer 
(BD Bioscience, New York, USA) following our previously 
described protocol (Liu et al. 2013).
For cytotoxicity analysis, target cells (1 × 105 cells; MDA-
MB-231, MCF-10A, MCF-7, hTERT-RPE1, or RB-Y79) 
were stained with 2 µM 5-carboxyfluorescein diacetate 
succinimidyl ester (CFSE). The CFSE-labeled target cells 
were washed and co-cultured with 2 × 106 CTLs. At 24 h 
later, the cells were washed twice and stained with 1 µg/ml 
propidium iodide (PI). The Annexin V Apoptosis Detection 
Kit (BD Bioscience, New York, USA) was used to evalu-
ate apoptosis according to the manufacturer’s instructions. 
The dual-color flow cytometry analysis was performed with 
FACSCalibur Flow Cytometer. To calculate the cytotoxicity 
in above experiments, we have already deduced the sponta-
neous mortality of both control and study group from the 
flow cytometry cytotoxicity read out in this work.
RNA interference of RB‑Y79 cells
RB-Y79 cells were transfected with SYK-homo-301 and 
SYK-homo-924 siRNAs (Genepharm, Shanghai, China) at 
100 nM using Lipofectamine® 3000 (Thermo Fisher Sci-
entific, USA) according to the manufacturer’s instructions. 
Scrambled siRNA was used as a negative control. Cells were 
cultured for 72 h and then used in the experiments. To avoid 
off-target effects, we used two pairs of siRNAs to carry out 
the RNA interference: SYK-homo-924, 5′-GUC GAG CAU 
UAU UCU UAU ATT-3′ and 5′-UAU AAG AAU AAU GCU 
CGA CTT-3′, as well as SYK-homo-301, 5′-GCA UGA GUG 
AUG GGC UUU ATT-3′ and 5′-UAA AGC CCA UCA CUC 
AUG CTT-3′. The sequences of control siRNAs (scrambled 
negative control) were 5′-UUC UCC GAA CGU GUC ACG 
UTT-3′ and 5′-ACG UGA CAC GUU CGG AGA ATT-3′.
SYK overexpression in hTERT‑RPE1 cells
The hTERT-RPE1 cells were infected by SYK–GFP lentivi-
rus at MOI 5 with the addition of 10 µg/ml polybrene. After 
24 h, 1 µg/ml Puromycin (Thermo Fisher Scientific, USA) 
was added to the media to select the stable SYK–GFP–RPE1 
cell line.
Immunofluorescence
Immunostaining was performed followed with our previ-
ously described method (Liu et al. 2013) but not the per-
meabilization step. The antibodies included SYK antibody 
(1:400, Cell-Signaling Technology, Danvers, USA), actin 
antibody (1:400, Sigma, St. Louis, USA), FITC-labeled goat 
anti-rabbit IgG, Alexa Fluor 555-labeled donkey anti-rabbit 
IgG, Alexa Fluor 350-labeled goat anti-mouse IgG (1:400, 
Beyotime Institute of Biotechnology, China), and TRITC-
conjugated Phalloidin (1:1000, Sigma, St. Louis, USA).
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Live‑cell video microscopy
We previously established a stable fluorescent RB-Y79 cell 
line expressing the LifeAct-GFP protein (RB-Y79–GFP) 
(Wang et  al. 2013). For live-cell video experiments, 
RB-Y79–GFP cells (5 × 103 cells) were plated on glass-
bottom dishes (MatTek, MA, USA) and kept at 37  °C 
in a humidified incubator for 2 h to adhere. Then, SYK-
DC–CTLs were added at a ratio of 10:1. After co-culture for 
12 h, cells were imaged every 5 min for 6–8 h at 37 °C using 
a Leica microscope. Images were then processed offline with 
the Image J software K1.45.
Quantitative real‑time polymerase chain reaction 
(qRT‑PCR)
SYK and GFP mRNA levels were determined by qRT-
PCR. Total RNA was obtained from 1 × 106 cells using the 
Aurum™ Total RNA Mini Kit (Bio-Rad, California, USA). 
Then, cDNA was synthesized by reverse transcription from 
1 µg total RNA using the iScript cDNA Synthesis Kit (Bio-
Rad, California, USA). The iQ SYBR Green SuperMix Kit 
(Bio-Rad, California, USA) was used for real-time PCR 
reaction according to the manufacturer’s instructions. Glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S 
rRNA was used as internal control. The nucleotide sequences 
of the qRT-PCR primers are listed in Table 1.
Statistical analysis
All data are presented as mean ± SEM. Because of the small 
sample size, the data failed to pass the D’Agostino–Pear-
son’s normality test. Thus, the significance of the difference 
between groups was evaluated with Mann–Whitney U test 
using the SPSS Statistics 19.0 software. A value of p < 0.05 
was considered statistically significant.
Results
SYK lentivirus enhances DC maturation 
and T‑lymphocyte activation in vitro
To develop functional antigen-loaded DCs, we first gen-
erated CTLs from peripheral blood mononuclear cells 
(PBMCs). CTLs are commonly  CD8+ and as such are able 
to recognize the complex comprising the major histocom-
patibility complex class I (MHC-I) molecule and the tumor 
antigen peptide on tumor cells, thus stimulating an effec-
tive and specific anti-tumor immune response (Ahmed and 
Bae 2014; Itoh and Shichijo 2005). We developed lentivirus 
Table 1  Nucleotide sequences of the primers used for qRT-PCR anal-
yses
Primer Sequence
SYK forward 5′-TCA GCG GGT GGA ATA ATC TC-3′
SYK reverse 5′-TGC AAG TTC TGG CTC ATA CG-3′
GFP forward 5′-CAC ATG AAG CAG CAC GAC TT-3′
GFP reverse 5′-GAT GCG ATT CAC CAG GGT AT-3′
GAPDH forward 5′-CGC ATC TTC TTG TGC AGT -3′
GAPDH reverse 5′-AAT GAA GGG GTC GTT GAT GG-3′
18S rRNA forward 5′-AAC TTT CGA TGG TAG TCG CCG-3′
18S rRNA reverse 5′-CCT TGG ATG TGG TAG CCG TTT-3′
Fig. 1  SYK lentivirus enhances DC maturation and T-lymphocyte 
activation in vitro. a CD86 marker (green signal) was spread all over 
the surface of DCs (left image). Numerous dendritic actin protrusions 
extended from the cell body (red, middle and right images). Scale bar 
equals 25 µm. b Normalized expression level of GFP in GFP-DCs 
and SYK in SYK-DCs. GAPDH was used as the internal control gene. 
c Quantification of CD80, CD83 and CD86 expression in WT-DCs, 
GFP-DCs, and SYK-DCs. d Proportions of  CD3+CD8+, TCRαβ+, 
 CD3+CD38+, and  CD3+HLA–DR+ in WT-DC–CTLs, GFP-DC–
CTLs, and SYK-DC–CTLs. Data were mean ± SEM from three inde-
pendent experiments. *p < 0.05, **p < 0.01
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expressing the SYK gene (Liu et al. 2013) and used the lenti-
virus to infect DCs and generate SYK-DCs. GFP lentivirus 
was used to establish GFP-DCs as a control. Representative 
images of cell morphology are shown in Fig. 1. As shown in 
Fig. 1a, numerous dendritic actin protrusions extended from 
the cell body (middle and right images), which is the typi-
cal morphology of a mature DC. The numerous actin dots 
(Fig. 1a, middle and right images) indicate the podosoma of 
DCs (Vignjevic and Montagnac 2008; Yamakita et al. 2011). 
They were well known as their strong migration ability and 
antigen assimilating (Baranov et al. 2014). Mature DCs 
were identified by CD86 immunofluorescent staining, char-
acterized by a green dotted appearance (Fig. 1a, left image) 
spreading all over the cell surface (Ohkuma et al. 2015).
To confirm lentivirus-mediated expression, we exam-
ined GFP-DCs and SYK-DCs by qRT-PCR analysis at 7 
days after infection. SYK expression in non-infected wild-
type DCs (WT-DCs) was negligible. In contrast, SYK-DCs 
showed over 400 times higher expression of SYK compared 
with WT-DCs (Fig. 1b). The GFP and SYK gene expression 
real-time amplification curves of WT-DCs, GFP-DCs, and 
SYK–DCs cells are shown in Supplemental Fig. 1a.
CD80, CD83, and CD86 are commonly used as mark-
ers of mature DCs. We evaluated the expression of these 
markers in DCs and found significantly different between 
the GFP-DC and SYK–DC groups compared with the con-
trol WT-DC group (Fig. 1c). The proportions of  CD80+, 
 CD83+, and  CD86+ cells were 29.67 ± 0.50, 16.70 ± 0.80, 
and 54.70 ± 2.40% in the WT-DC group, 43.78 ± 0.56, 
45.55 ± 0.69, and 98.34 ± 0.91% in the GFP-DC group, and 
38.11 ± 0.50, 43.43 ± 0.54, and 97.73 ± 0.25% in the SYK-
DC group, respectively. These data mean overexpression of 
SYK results in a higher degree state of DC maturation.
We next co-cultured autologous T cells with mature WT-
DCs, GFP-DCs and SYK-DCs for 7 days separately to obtain 
WT-DC–CTLs, GFP-DC–CTLs, and SYK-DC–CTLs. T-cell 
markers (CD3, CD8, and TCRαβ) are used as activation 
markers, while these are molecules that been expressed on all 
T cells including the cells with resting or naïve phenotype. 
CD38 and HLA-DR are commonly used to identify acti-
vated T cells (Loewendorf et al. 2014; Tarbox et al. 2014). 
Testing the levels of these markers is important, because 
they are crucial for antigen recognition and specific cyto-
toxicity. Thus, we examined the proportions of  CD3+CD8+, 
TCRαβ+,  CD3+CD38+, and  CD3+HLA-DR+ populations 
using flow cytometry to demonstrate the activity of dif-
ferent T-cell groups. Higher proportion of CD3 + CD8+, 
TCRαβ+, CD3 + CD38 +, and CD3 + HLA-DR + cells 
were detected, which proportion of  CD3+CD8+, TCRαβ+, 
 CD3+CD38+, and  CD3+HLA-DR+ populations were 
68.02 ± 1.56, 69.81 ± 0.65, 90.98 ± 1.34, and 29.40 ± 1.56% 
in the WT-DC–CTL group, 80.11 ± 0.90, 73.44 ± 0.74, 
95.41 ± 0.86, and 58.11 ± 1.27% in the GFP-DC–CTL 
group, and 76.01 ± 1.47, 75.49 ± 0.62, 97.15 ± 1.10, and 
59.96 ± 1.12% in the SYK-DC–CTL group, respectively, as 
shown in Fig. 1d. This phenotype prove that SYK-DC could 
active T cells better than wild-type DC.
Taken together, these results demonstrated that the SYK 
gene was successfully expressed in DCs by lentivirus infec-
tion and that SYK-DCs generated in vitro could stimulate 
naïve T cells to become active and express higher levels of 
 CD3+CD8+, TCRαβ+,  CD3+CD38+, and  CD3+HLA-DR+ 
compared with controls. The flow cytometry scatter plots 
are shown in Supplemental Fig. 2.
SYK‑DC–CTLs show specific cytotoxicity 
against SYK‑positive cells but not SYK‑negative cells 
in vitro
To examine the effect of SYK in CTL-specific cytotoxicity 
against RB cells, we first evaluated basal SYK expression 
levels in human RB RB-Y79 and human retinal pigment 
epithelium cells hTERT-RPE1 cell lines using qRT-PCR 
and an immunofluorescence assay. Figure 2a shows that the 
normalized expression level of SYK in RB-Y79 cells was five 
times higher than that of hTERT-RPE1 cells (p < 0.05). The 
real-time amplification curves are shown in Supplemental 
Fig. 1b. Immunofluorescence results further revealed that 
SYK was expressed on the surface of RB-Y79 cells, but 
it was undetectable on the surface of hTERT-RPE1 cells 
(Fig. 2b). Although the immunofluorescent picture in Fig. 2b 
showing SYK on the cell surface of RB-Y79 displays a high 
background, we provided a “no primary antibody" control 
to show the specific staining with the antibody shown as 
Supplemental Fig. 3a.
Using different cell lines, we compared the consistency of 
SYK expression levels which is important for the specificity 
of cytotoxicity. As RB-Y79 is the only available malignant 
RB cell line, we also tested the universal property of SYK-
DC–CTL. SYK high expression cell lines MCF-7 original 
from breast cancer was checked by western blotting using 
SYK-negative cell lines MDA-MB-231 and MCF-10A as 
controls (George et al. 2005; Mahabeleshwar and Kundu 
2003). As shown in Fig.  2c, MCF-7 and RB-Y79 cells 
clearly showed high expression of SYK protein.
As the DC–CTL response is largely dependent on HLA 
types (Sui et al. 2015), we checked the histocompatibility of 
DC–CTL (original PBMC substitute) with target cell lines. 
As shown in Fig. 2d, the proportion of HLA-A2+ cells in 
PBMCs, MDA-MB-231, MCF-10A, MCF-7, hTERT-
RPE1, and RB-Y79 cells was 99.66 ± 0.44, 13.64 ± 2.02, 
37.07 ± 2.78, 5.29 ± 0.89, 5.36 ± 0.79, and 75.90 ± 5.11%, 
respectively. The flow cytometry scatter plots are shown in 
Supplemental Fig. 3b.
We next evaluated the specific cytotoxicity of SYK-
DC–CTLs against two groups of cells, using WT-DC–CTLs 
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and GFP-DC–CTLs as controls. Group one included SYK-
negative cell lines (MDA-MB-231, MCF-10A, and hTERT-
RPE1), while group two included SYK-positive cell lines 
(MCF-7 and RB-Y79). Our flow cytometry results showed 
that the group two SYK-positive cell lines showed higher 
levels of cytotoxicity upon co-culture with SYK-DC–CTLs 
compared with the control WT-DC–CTLs and GFP-
DC–CTLs. In contrast, the group one SYK-negative cell 
lines showed no significant differences in cytotoxicity upon 
co-culture with SYK-DC–CTLs or the controls (Fig. 2e). 
The flow cytometry scatter plots of the cytotoxicity experi-
ments are shown in Supplemental Fig. 4.
Next, we analyzed the cytotoxic activity of SYK-
DC–CTLs against GFP stably expressing RB-Y79 cells 
(RB-Y79-GFP) (Liu et  al. 2013) by video microscopy. 
Figure 2f shows a RB-Y79-GFP cell attacked by several 
SYK-DC–CTL cells. The disappearance of GFP fluores-
cence occurred about 1 h after co-culture, which means 
that the target cells were induced to undergo apoptosis by 
SYK-DC–CTLs. Quantification of the live imaging results 
is shown in Fig. 2g. After 50 min of SYK-DC–CTLs and 
RB–Y79–GFP co-culture, the mean gray value of fluo-
rescence in target cells GFP-K562 slumped. Furthermore, 
compared to the method using tumor lysis antigen-loaded 
Fig. 2  SYK-DC–CTLs show specific cytotoxicity against SYK-
positive cells but not SYK-negative cells in  vitro. a Quantifica-
tion of qRT-PCR results of SYK expression in RB-Y79 cells and 
hTERT-RPE1 cells. 18S rRNA was used as the internal control gene. 
*p < 0.05. b Immunofluorescence results showed SYK (green signal) 
expression on the surface of RB-Y79 cells (bottom panel). No SYK 
expression was detected on the surface of hTERT-RPE1 cells (top 
panel). Scale bar equals 25 µm. c Western blot analysis of SYK pro-
tein expression levels in MDA-MB-231, MCF-10A, MCF-7, hTERT-
RPE1, and RB-Y79 cells. Actin was used as a loading control. d Flow 
cytometry analysis of HLA-A2 in PBMC, MDA-MB-231, MCF-10A, 
MCF-7, hTERT-RPE1, and RB-Y79 cells. e Flow cytometry analy-
sis of apoptosis in MDA-MB-231, MCF-10A, MCF-7, hTERT-RPE1, 
and RB-Y79 cells co-cultured with WT-DC–CTL, GFP-DC–CTL, 
and SYK-DC–CTL cells. f Time-lapse video of SYK-DC–CTL cells 
(red arrow) co-cultured with an RB-Y79-GFP cell (green, white 
arrow). Scale bar equals 25 µm. g Mean gray value (MGV) of fluores-
cence intensity of RB-Y79-GFP cells in the time-lapse video above. 
Data were given as mean ± SEM from three independent experiments. 
*p < 0.05, **p < 0.01
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DC–CTLs, we measured the efficiency of SYK-DC–CTL 
that resulted in a 50% increasing of cytotoxicity against 
RB-Y79 cells (Supplemental Fig. 5a, c) as well as a twice 
ratio of RB-Y79 cells apoptosis (Supplemental Fig. 5b, d).
Expression of SYK in RB‑Y79 cells in vitro mediates 
SYK‑DC cytotoxicity
To further characterize the specific cytotoxicity of SYK-
DC–CTLs against RB-Y79 cells, we silenced SYK in 
RB-Y79 cells (SYKRNAiRB-Y79) and confirmed significantly 
lower SYK levels in SYKRNAiRB-Y79 cells than negative con-
trol siRNA-treated RB-Y79 (NC-RB-Y79) cells (p < 0.01) 
(Fig. 3a). We observed differences in viability when using 
siRNA for the silence of SYK in the RB-Y79 cell line (data 
shown in Supplemental Fig. 5e). NC-RB-Y79 was observed 
spontaneous mortality of 1.35%, and SYKRNAiRB-Y79 cell 
group presented mortality of 4.56%. However, the mortal-
ity of SYK-DC–CTL treated SYKRNAiRB-Y79 cell group is 
more than 30%, which means the cell death resulted from the 
specific cytotoxicity of T cells. To calculate the cytotoxicity 
in our experiments, we have already deduced the spontane-
ous mortality of NC–RB-Y79 and SYKRNAiRB-Y79 cells in 
Fig. 3b. SYK-DC–CTLs had remarkably less cytotoxic activ-
ity against SYKRNAiRB-Y79 cells compared with the NC-RB-
Y79 cells. To further characterize the key role of SYK in the 
specific cytotoxicity of SYK-DC–CTLs, we overexpressed 
SYK in SYK-negative hTERT-RPE1 cells and confirmed 
increasing of relative mRNA levels of SYK (Fig. 3c) and 
elevated SYK expression (Fig. 3d) in SYK–GFP–RPE1 cells 
compared with wild-type hTERT-RPE1 cells. Moreover, the 
SYK protein was confirmed to be existed on the surface of 
SYK–GFP–RPE1 cells (Fig. 3e) using SYK monoclonal 
antibody rather existing on the surface of wild-type hTERT-
RPE1 cells. The cytotoxicity of SYK-DC–CTLs against 
SYK overexpressed hTERT-RPE1 cells was significantly 
increased compared with that in wild-type hTERT-RPE1 
cells (Fig. 3f). Bundling all above results, it clearly dem-
onstrates that SYK protein expression in RB-Y79 cells can 
induce specific cytotoxicity by SYK-DC–CTLs.
SYK‑DC–CTLs exhibit specific cytotoxicity 
against carboplatin‑resistant RB‑Y79 cells in vitro
Carboplatin is a commonly used chemotherapeutic drug 
for RB treatment. Although the treatment can be relatively 
effective at the beginning of the therapy, as the treatment 
continues, the patients can develop resistance to carboplatin, 
increasing the chances of tumor regrowth and formation of 
secondary metastases (Assayag et al. 2016).
To assess whether our experimental immunotherapy 
could be effective against carboplatin-resistant RB cells, we 
analyzed the cytotoxic activity of SYK-DC–CTLs against 
carboplatin-resistant RB-Y79 cells (RB-Y79-R) (Wang et al. 
2013). We first confirmed resistance to carboplatin by cul-
turing RB-Y79-sensitive (RB-79-S) and RB-Y79-Resistant 
cells(RB-Y79-R) with 40 µg/ml carboplatin for 24 and 48 h 
and examining cell viability using trypan blue staining 
Fig. 3  Expression of SYK on RB-Y79 cells in  vitro mediates 
T-lymphocyte-specific cytotoxicity. a Quantification of qRT-PCR 
analysis of SYK in RB-Y79 cells transfected with siRNA against 
SYK (SYKRNAiRB-Y79 cells) or control siRNA (NC-RB-Y79 cells). 
GAPDH was used as the internal control gene. b Flow cytometry 
analysis of the cytotoxic activity of SYK-DC–CTLs against NC-RB-
Y79 and SYKRNAiRB-Y79 cells. Data were mean ± SEM from three 
independent experiments. **p < 0.01. c Quantification of qRT-PCR 
analysis of SYK in SYK–GPF–RPE1 cells and wild-type hTERT-
RPE1 cells. GAPDH was used as the internal control. d The relative 
SYK protein expression levels in hTERT-RPE1 and SYK–GFP–
RPE1 cells were determined by western blotting. Actin was used 
as a loading control. e Immunofluorescent staining of monoclonal 
SYK antibody showed that SYK (red signal) existed on the surface 
of SYK–GFP–RPE1 cells (bottom panel) but not on that of hTERT-
RPE1 cells (top panel). Scale bar equals 25 µm. f Flow cytometry 
analysis of the cytotoxic activity of SYK-DC–CTL cells against 
hTERT-RPE1 and SYK–GFP–RPE1 cells. Data were mean ± SEM 
from three independent experiments. **P < 0.01
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(Fig. 4a) and PI staining (Fig. 4b). RB-Y79-R cells largely 
survived in the presence of carboplatin (~ 98% survival rate 
after 48 h) while 80% of RB-Y79-S survived during the 
same time interval (Fig. 4a, b).
We next evaluated the ability of SYK-DC–CTLs to 
induce cytotoxicity of RB-Y79-R cells. Ag-DC–CTLs were 
used as control to judge the intensity of SYK-DC–CTL’s 
cytotoxicity. Our results revealed that the cytotoxicity 
of GFP-DC–CTLs, Ag-DC–CTLs, and SYK-DC–CTLs 
against RB-Y79-R cells was 19.14 ± 0.82, 36.84 ± 1.01, and 
55.67 ± 1.26%, respectively (Fig. 4c–e). Compared with 
Ag-DC–CTLs, SYK-DC–CTL showed a stronger cytotoxic 
effect against RB-Y79-R cells.
Discussion
The major limitations to achieving effective cancer treat-
ments are the lack of specificity in targeting cancer cells and 
reducing side effects. Thus, the identification of specific tar-
gets has become a necessity for the development of effective 
targeted therapies. Based on the recent report identifying 
SYK as an important oncogene in RB (Zhang et al. 2012), 
we evaluated the use of SYK protein as a putative target to 
deliver selective immunotherapy against RB cells. Impor-
tantly, this study is the first report on the expression of SYK 
on DCs and the first demonstration that SYK expression con-
fers specificity of immunoreactivity against RB cells with no 
immunoreactivity on normal retina cells in vitro.
In our study, the HLA histocompatibility seems important 
for the DC–CTL response. However, we noticed that the 
MCF-7 cell line using as SYK-positive control was recog-
nized by the T cells although this cell line is not HLA-A2 
positive. The reasonable explanation could be that HLA-
A2 is one of HLA class I family which consists of HLA-
A, HLA-B, and HLA-C (Rabasa et al. 2017). Although the 
MCF-7 cell line is not HLA-A2 positive, SYK antigen could 
be presented by the other HLA subtypes.
In agreement with the previous study (Zhang et al. 2012), 
our data confirm that the expression level of SYK is low in 
normal retina cells but is high in an RB cell line (RB-Y79). 
Although previous works showed that SYK accumulated in 
the cytoplasm in RB cells (Zhang et al. 2012), our immuno-
fluorescent staining results showed SYK expression on the 
cell surface. SYK protein localization on the cell membrane 
facilitates activated CTLs to specifically recognize the anti-
gens present on the surface of RB-Y79 cells. This is key for 
specific lymphocyte-based immunotherapy. SYK is also a 
member of a family of cytoplasmic non-receptor tyrosine 
kinases. This confers an additional advantage for its use in 
targeted cell immunotherapy because RB-Y79 cells express 
the SYK protein on the cell surface, allowing it to be rec-
ognized by cytotoxic immune cells, while hematopoietic 
cells, which express cytoplasmic SYK, may be protected 
from SYK-driven immune cytotoxic activity (Chauhan et al. 
2016). Although we demonstrated SYK gene expression in 
SYK-DCs by qRT-PCR, we failed to detect SYK protein on 
the surface of infected DC cells using flow cytometry (data 
not shown). The possible reasons why we failed to detect 
the SYK signal in DCs could due to two aspects. Firstly, in 
a classical pathway in DCs, the antigen is cleaved into pep-
tides by endosomal proteases, particularly cathepsin S, and 
bound by class I molecules probably in the endocytic com-
partment itself (Rock and Shen 2005). Secondly, the pro-
cessed antigen could not be presented everlastingly on the 
DC surface, published data have also explained how duration 
of antigen presentation affects the dynamics of T-cell–DC 
Fig. 4  SYK-DC–CTLs exhibit specific cytotoxicity against carbopl-
atin-resistant RB-Y79 cells in vitro. The cell viability of RB-79-S and 
RB-Y79-R cells in media containing carboplatin was measured by 
trypan blue staining (a) and PI staining (b). c Cytotoxicity and apop-
tosis analysis of GFP-DC–CTL cells, Ag-DC–CTL cells and SYK-
DC–CTL cells against RB-Y79-R cells were detected by flow cytom-
etry. The figures showed the proportion of dead RB-Y79-R cells (top 
panel) and apoptotic RB-Y79-R cells (bottom panel). d Cytotoxicity 
of GFP-DC–CTL cells, Ag-DC–CTL cells and SYK-DC–CTL cells 
against RB-Y79-R cells. e Quantification of apoptotic RB-Y79-R 
cells after co-culture with GFP-DC–CTL cells, Ag-DC–CTL cells 
or SYK-DC–CTL cells. Data were given as mean ± SEM from three 
independent experiments. *p < 0.05, **p < 0.01
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interactions and consequently determine immune response 
(Benson et al. 2015). Thus, it is easy to understand why we 
see no staining for SYK on the pulsed DCs.
Cell immunotherapy has advantages over the use of drugs 
for cancer treatment, as immunotherapy is highly tumor-
specific and, for the most part, lacks undesirable side effects. 
Our results also suggest that SYK-DC–CTLs may also be 
used to treat other tumors that express SYK protein on the 
surface of cancerous cells. SYK is upregulated in human 
prostate cancer and is associated with malignant progression 
(Ghotra et al. 2015). SYK methylation was also correlated 
with poor overall survival of colorectal cancer (Yang et al. 
2013) and SYK is also overexpressed in ovarian cancer (Sul-
tan et al. 2011). Further studies will be needed to shed light 
on the use of SYK for targeted cancer therapy.
Based on our findings, we propose that designed lentivi-
rus-targeted immunotherapy may provide a foundation for 
therapeutic innovation against a broad spectrum of cancers, 
especially leukemia, lymphomas (Ma et al. 2015) and RB 
treatment (this paper). However, the exact curative effect 
of SYK-DC–CTL immunotherapy still needs to be demon-
strated through animal experiments and clinical trials.
In summary, we found that SYK-modified DC–CTLs were 
specific and highly cytotoxic against multiple SYK-positive 
cell lines, especially RB cells, while they had a minimal 
effect on SYK-negative cell lines including normal retinal 
cells. This suggests a promising specific and safe approach 
for RB treatment. Our study constitutes one of the first dem-
onstrations that lentivirus-targeted immunotherapy may be 
an effective means for treating cancers and indicates that 
SYK may prove to be a suitable candidate for targeted ther-
apy of RB.
Conclusions
In conclusion, our data suggest that SYK could be a poten-
tial immunotherapy target antigen presented by DCs. These 
observations indicate that CTLs were largely activated 
by SYK overexpressed DCs with specific cytotoxicity on 
RB-Y79 cells. Moreover, we propose SYK as a candidate 
target for treatment of chemoresistant RB.
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